MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH STABLE ASTHMA CONTROL

被引：0
|
作者：
Mehta, V.
Worm, M.
Chiesa, Z.
Natalie, C.
Dawson, Z.
Zhong, J.
Diemert, S.
Boguniewicz, M.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2023年 / 131卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P280
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [31] Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials
    Gold, Linda Stein
    Thaci, Diamant
    Thyssen, Jacob P.
    Gooderham, Melinda
    Laquer, Vivian
    Natalie, Chitra R.
    Zhao, Fangyi
    Meskimen, Eric
    ElMaraghy, Hany
    Montmayeur, Sonia
    Jimenez, Gemma
    de Bruin-Weller, Marjolein
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [32] Symptom burden of patients with moderate-to-severe atopic dermatitis
    Alexander Egeberg
    Peter Anderson
    James Piercy
    Lucy Massey
    Joseph C. Cappelleri
    Gerardo A. Encinas
    Claire Feeney
    Marco Dibonaventura
    European Journal of Dermatology, 2021, 31 : 752 - 758
  • [33] Symptom burden of patients with moderate-to-severe atopic dermatitis
    Egeberg, Alexander
    Anderson, Peter
    Piercy, James
    Massey, Lucy
    Cappelleri, Joseph C.
    Encinas, Gerardo A.
    Feeney, Claire
    Dibonaventura, Marco
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (06) : 752 - 758
  • [34] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
    Nettis, Eustachio
    Patella, Vincenzo
    Lombardo, Carla
    Detoraki, Aikaterini
    Macchia, Luigi
    Di Leo, Elisabetta
    Carbonara, Monica
    Canonica, Giorgio W.
    Bonzano, Laura
    ALLERGY, 2020, 75 (10) : 2653 - 2661
  • [35] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [36] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [37] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
    Zirwas, Matthew J.
    Boguniewicz, Mark
    Rosmarin, David
    Fuxench, Zelma Chiesa
    Warren, Richard B.
    Torres, Tiago
    de Bruin-Weller, Marjolein
    Dawson, Zach
    Atwater, Amber Reck
    Elmaraghy, Hany
    Pierce, Evangeline
    Bardolet, Laia
    Zhong, Jinglin
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
  • [38] Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
    Lio, Peter A.
    Armstrong, April
    Gutermuth, Jan
    Nosbaum, Audrey
    Sofen, Howard
    Gil, Esther Garcia
    Casillas, Marta
    Chen, Sherry
    Sun, Luna
    Pierce, Evangeline
    Elmaraghy, Hany
    Dawson, Zach
    Torres, Tiago
    DERMATOLOGY AND THERAPY, 2024, 14 (07) : 1929 - 1943
  • [39] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 : 169 - 182
  • [40] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Rand, Kim
    Ramos-Goni, Juan Manuel
    Akmaz, Bulent
    Sole-Feu, Laia
    Armario-Hita, Jose-Carlos
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 169 - 182
12345